Peer-reviewed veterinary case report
Transdermal methimazole for treating hyperthyroid cats
By Hoffmann, G et al.·Published in Journal of Feline Medicine and Surgery·2003·Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 708030/8410, USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Transdermal methimazole treatment in cats with hyperthyroidism
- Species:
- cat
Plain-English summary
A group of 13 cats with hyperthyroidism (a condition where the thyroid gland produces too much hormone) were treated with a transdermal gel containing methimazole, applied to the inner ear. After about 4 weeks, the cats showed clinical improvement and had significantly lower levels of thyroid hormone compared to before treatment. The positive results continued when they were checked again after about 5 months, and no side effects were reported. This treatment option appears effective for managing hyperthyroidism in cats.
People also search for: cat hyperthyroidism treatment · transdermal methimazole for cats · symptoms of hyperthyroidism in cats
Abstract
The objectives of this study were to assess serum thyroxine concentrations and clinical response in hyperthyroid cats to treatment with transdermal methimazole, and to determine if further investigation is indicated. Clinical and laboratory data from 13 cats with hyperthyroidism were retrospectively evaluated. Methimazole (Tapazole, Eli Lilly) was formulated in a pleuronic lecithin organogel (PLO)-based vehicle and was applied to the inner pinna of the ear at a dosage ranging from 2.5 mg/cat q 24 h to 10.0 mg/cat q 12 h. During the treatment period, cats were re-evaluated at a mean of 4.3 weeks (recheck-1), and again at a mean of 5.4 months (recheck-2). Clinical improvement was observed, and significant decreases in thyroxine concentrations were measured at recheck-1 (mean: 39.57 nmol/L, SEM: 14.4, SD: 41.2) and recheck-2 (mean: 36.71 nmol/L, SEM: 13.9, SD: 45.56) compared to pretreatment concentrations (mean: 97.5 nmol/L, SEM: 11.42, SD: 39.5). No adverse effects were reported.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1016/s1098-612x(02)00095-5